Special Report: Developer of a new class of synthetic anti-infectives, Recce Pharmaceuticals is boosting its balance sheet securing a debt facility of up to ~$30 million to support Phase III ...

Recce Pharmaceuticals secures a debt facility of up to ~$30m to support Phase III registrational trials in Indonesia and Australia. Initial non-dilutionary funding of ~$11.5m supporting two ...

Special Report: Recce Pharmaceuticals has secured patent acceptance in China for its synthetic anti-infectives RECCE® 327 (R327) and RECCE® 529 (R529) as it targets the growing global health ...

strengthening cash position to ~$27.5m Special Report: Developer of a new class of synthetic anti-infectives, Recce Pharmaceuticals is boosting its balance sheet securing a debt facility of up to ...

Recce receives firm commitments to place the full shortfall from its entitlement offer raising a total of $15.8 million to ...

Acceptance strengthens the company’s global patent portfolio Recce tackling global health problem of antibiotic-resistant superbugs Special Report: Recce Pharmaceuticals has secured patent ...

ASX:RCE Earnings and Revenue Growth May 26th 2025 Take a more thorough look at Recce Pharmaceuticals' financial health with this free report on its balance sheet. Recce Pharmaceuticals ...

Recce Pharmaceuticals secures patent acceptance ... global health problem of antibiotic-resistant superbugs Special Report: Recce Pharmaceuticals has secured patent acceptance in China for its ...